🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

QMS Medical Allied Services Limited QMSMEDI NSEPHARMA

Healthcare · Medical Instruments & Supplies · India
https://qmsmas.com
Company Profile ↓
₹172.12
+127.22% 1Y
Mkt Cap₹332.84 Cr
P/E29.22
P/B6.32
Div. Yield0.25%
52W High₹216.79
52W Low₹71.81
Book Value₹29.67
EPS (TTM)₹5.89

Company Overview

QMS Medical Allied Services Limited distributes medical and healthcare products in India. The company also offers BP monitors, stethoscopes, surgical sterilization kits, BMI scales, and orthotics, as well as Q-Devices; and point-of-care testing devices, rapid diagnostic kits, and in-clinic multipara devices. It also operates QMSMEDS, an e-commerce platform that sells healthcare devices of various brands. In addition, the company provides patient support solutions, including tele counselling, in clinic activation, advanced respiratory screening programs, orthopedic screening and wellness programs, disease management, and home care solutions; and patient screening camps for diabetes, cardiology, orthopedic, respiratory screening, gynaecology, gastroenterology, ophthalmic, and dietitian camp. Further, it offers Educamedics, which provides customized scientific content in the form of conferences, online courses, webinars, recorded lectures, and others; and digital and brand services. QMS Medical Allied Services Limited was founded in 1994 and is based in Mumbai, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 18.9%.

Consistent Profit Growth

Net profit has compounded at 23.2% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 18.4% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 29.2, below the sector median of 37.4.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹172.88 Cr (+10.8% YoY); net profit ₹11.92 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +22.3%, earnings +25.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 18.4%, profit CAGR 23.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:18.44%
1 Year:22.30%

Compounded Profit Growth

5 Years:23.16%
1 Year:25.00%

Stock Price Performance

1 Year:+127.22%
6 Months:+91.74%
3 Months:+50.60%
1 Month:-16.43%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 69% of range
₹71.81 ₹216.79
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)46.03 · Neutral
Price Performance
1M-16.43%
3M+50.60%
6M+91.74%
1Y+127.22%
Valuation vs Sector

P/E of 29.22 is below the sector median of 37.41 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 18.4% over 5 years.
  • Profit CAGR of 23.2% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
29.22
Industry PE
37.41
Forward P/E est.
23.38
PEG Ratio
-
Book Value
₹29.67
Price to Book
6.32
P/S
1.98
EV/EBITDA
15.40
Dividend Yield
0.25%

Growth (CAGR)

Revenue 5Y
18.44%
Profit 5Y
23.16%
Revenue (YoY)
22.30%
Earnings (YoY)
25.00%

Profitability & Returns

ROCE
18.91%
ROE
11.44%
ROA
5.60%
Profit Margin
5.92%
Op Margin
12.03%
Gross Margin
49.32%
EPS (Latest Qtr)
₹0.89
EPS (TTM)
₹5.89

Balance Sheet & Liquidity

Debt/Equity
0.65
Quick Ratio
1.05
Current Ratio
1.56
Debt
₹74.48 Cr
Total Assets
₹212.85 Cr
Current Assets
₹142.01 Cr
Working Capital
₹50.74 Cr

Ownership

Promoter Holding
-
Chg in Prom Hold
-
FII / Inst Holding
-
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹332.84 Cr
Total Revenue (TTM)
₹183.25 Cr
EBITDA
₹27.29 Cr
Free Cash Flow
₹13.65 Cr
Operating Cash Flow
₹19.44 Cr
Shares Outstanding
₹1.93 Cr
Gross Margin
49.32%
Payout Ratio
8.53%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 QMSMEDI QMS Medical Allied Services Limited NSEPHARMA 172.12 29.22 ₹332.84 Cr 0.25% 18.91% 11.44% 18.44% 23.16%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,770.00 35.12 ₹4.25 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,945.50 90.45 ₹2.64 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,595.00 73.40 ₹1.75 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,348.00 116.07 ₹1.27 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
6 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,240.50 27.65 ₹1.24 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,459.00 58.23 ₹1.22 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 664.75 173.11 ₹1.15 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,387.00 33.26 ₹1.12 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --44.58 Cr46.49 Cr44.70 Cr37.26 Cr44.42 Cr
Cost of Revenue --21.93 Cr25.93 Cr25.57 Cr18.86 Cr22.26 Cr
Gross Profit --22.65 Cr20.56 Cr19.13 Cr18.39 Cr22.16 Cr
Operating Expenses --17.63 Cr14.98 Cr13.15 Cr12.67 Cr17.51 Cr
Operating Income --5.02 Cr5.58 Cr5.98 Cr5.73 Cr4.65 Cr
EBITDA --7.47 Cr6.76 Cr7.14 Cr7.05 Cr5.99 Cr
Interest Expense --1.41 Cr1.42 Cr1.36 Cr1.75 Cr2.02 Cr
Pretax Income --4.69 Cr4.48 Cr4.84 Cr4.27 Cr2.84 Cr
Tax Provision --1.09 Cr1.33 Cr1.27 Cr1.10 Cr82.47 L
Net Income --3.61 Cr2.93 Cr3.12 Cr3.17 Cr2.02 Cr
Diluted EPS --1.841.621.711.240.89

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -104.04 Cr122.13 Cr156.01 Cr172.88 Cr
Cost of Revenue -77.88 Cr79.92 Cr81.60 Cr92.63 Cr
Gross Profit -26.16 Cr42.20 Cr74.41 Cr80.25 Cr
Operating Expenses -15.84 Cr27.30 Cr52.83 Cr58.31 Cr
Operating Income -10.32 Cr14.91 Cr21.58 Cr21.94 Cr
EBITDA -11.78 Cr18.80 Cr27.12 Cr26.93 Cr
Interest Expense -2.00 Cr3.13 Cr4.64 Cr6.55 Cr
Pretax Income -8.71 Cr12.24 Cr18.66 Cr16.44 Cr
Tax Provision -2.32 Cr3.23 Cr4.96 Cr4.52 Cr
Net Income -6.38 Cr9.00 Cr13.70 Cr11.92 Cr
Diluted EPS 5.923.864.986.65-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -117.74 Cr135.32 Cr189.79 Cr212.85 Cr
Current Assets -86.93 Cr105.77 Cr120.03 Cr142.01 Cr
Cash & Equivalents -2.37 Cr30.53 L1.07 Cr1.20 Cr
Inventory -29.93 Cr37.58 Cr39.33 Cr45.92 Cr
Receivables -39.04 Cr41.39 Cr43.24 Cr67.32 Cr
Total Liabilities -47.33 Cr56.81 Cr82.69 Cr98.88 Cr
Current Liabilities -45.40 Cr53.97 Cr73.13 Cr91.27 Cr
Long Term Debt -1.46 Cr2.37 Cr9.44 Cr6.97 Cr
Total Debt -25.52 Cr34.55 Cr60.29 Cr74.48 Cr
Total Equity -70.40 Cr78.51 Cr89.71 Cr104.19 Cr
Shares Outstanding 1.81 Cr1.81 Cr1.81 Cr1.81 Cr-

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow --7.54 Cr1.36 Cr23.68 Cr19.44 Cr
Investing Cash Flow --25.10 Cr-2.73 Cr-45.49 Cr-20.42 Cr
Financing Cash Flow -31.74 Cr40.89 L22.33 Cr1.11 Cr
Capital Expenditure --1.69 Cr-2.56 Cr-3.44 Cr-5.79 Cr
Free Cash Flow --9.23 Cr1.36 Cr20.24 Cr13.65 Cr
Net Change in Cash --89.69 L-96.10 L52.44 L13.10 L

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -25.1%34.6%47.7%46.4%
Operating Margin % -9.9%12.2%13.8%12.7%
Net Margin % -6.1%7.4%8.8%6.9%
ROE % -9.1%11.5%15.3%11.4%
ROCE % -14.3%18.3%18.5%18.0%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for QMSMEDI

Google News hu, 30 Apr 2026

Here's Why QMS Medical Allied Services (NSE:QMSMEDI) Has Caught The Eye Of Investors - Simply Wall St

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxQUXBnc1V3UmpIQlJiNTVHSVFXTWpvU2pCUjFqZVZHMGRJWXhlaGs5WUJpYjhaWGpYTGpMN0h0NDZoSXRoVDJWTEJVTm0yTGV3N09VNWxTcW44MlBoNFZidG91TW9GQVBVV0p3M25lRS1nMzVVRnB2QUVpOWQ0UEdaZWNoMkNyWmJrTzJ5bU…

Google News Wed, 26 Oct 2022

QMSMEDI Stock Price and Chart — NSE:QMSMEDI - TradingView

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE9aVDBuRW56NEE1RjdaR2Qxb3FoQTZuUHJxYk1HMjR0cG9JTFl3cFJScTFnX0lqWnVWdDZVeVpLNFI4Q0NYOHVhQkhLX3dDQnNvMU5leDlzRUc4N1la?oc=5" target="_blank">QMSMEDI Stock Price and Chart — NSE:QMSMEDI…

Google News Mon, 05 Oct 2026

QMS Medical Allied Services Ltd. Lower Circuit: Price and Key Data - Univest

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE1lb0tFQVZZeWJJSXM4Qkx2OTNGeUFNRC1IR3U5RkNjLW9QYU82cXRWVFRMNnZ2SUtEVmVtSTVkUF9HaVg4b2JrMjduaW8teDBlaXZCNGZ4YlVHa1hNa0psazVzQXo4eHgxTGJrY2laYi1PcFNIb2hLVjZOZFhiQQ?oc=5" target="_blan…

Google News Wed, 14 Oct 2026

QMS Medical Allied Services (NSE:QMSMEDI): What Does Its Reg 74(5) Filing for Q2 FY27 Confirm? - Kalkine India

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxOZzlfeTNlTUZUSXpSYXppcm1UeEw3VFlPZlN3dVBLREZRaVR2NmxBcV9ORnJyV2Q4RTR0Y2hhN1RVeV9EOTR2TXpfVlJSZHFHU1lBU0lOSlRLZElZVlR5dXFmcTlWR2s0YXBwYVJrTzJ1LUJBVXhuMzI5dTY4UWJUWWtMdG1hVmxRMVdxQW…

Google News ue, 29 Sep 2026

QMS Medical Allied Services Ltd. Upper Circuit: Price and Key Data - Univest

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE5oNEhmRzJOQXRITlM1aGNzLUYxbWppT1ZZTmFkejNZRC1hd3dRUnhGT3VrNWJ5N00zci1jX3dFNlc1NjNLRTdYN3JwQkRsUHlndmhUTndIcmJIaEtpdjB0SW01b3ltUGRlLVU2UjhmTElERTdGcjI4YWNjRVladw?oc=5" target="_blan…

Google News Fri, 14 Oct 2022

QMS Medical Allied Services (NSEI:QMSMEDI) - Stock Analysis - Simply Wall St

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQenMzM25sbEl5NnFaeTdjMTBoVzY5ZFJzWURlNXdIY2EwdVZBMFVtQVR2UVhFNFpVblhYV1E2a2g5YkpCUjRlLUVQMlpwWGpQUFlXRlVVVU5JQmxzZ2l4b1BUY21rbF9uUWRUYVRCdXhZbG1DQkg3cmJhMlRYMTFLSUNpaWpsbFRZa3dtZk…

QMSMEDI — Frequently Asked Questions

What is the current share price of QMS Medical Allied Services Limited (QMSMEDI)?

As of 2026-11-04 05:56 IST, QMS Medical Allied Services Limited (QMSMEDI) trades at ₹172.12 on NSE. Its 52-week range is ₹71.81 to ₹216.79.

What is the market capitalisation of QMSMEDI?

QMS Medical Allied Services Limited (QMSMEDI) has a market capitalisation of ₹332.84 Cr on NSE.

What is the P/E ratio of QMSMEDI?

QMSMEDI trades at a trailing price-to-earnings (P/E) ratio of 29.22. The industry average P/E is 37.41. Its price-to-book (P/B) ratio is 6.32.

Does QMSMEDI pay a dividend?

QMS Medical Allied Services Limited (QMSMEDI) currently offers a dividend yield of 0.25%.

What is the return on equity (ROE) of QMSMEDI?

QMSMEDI has a return on equity (ROE) of 11.44%. Its return on capital employed (ROCE) is 18.91%.

Is QMSMEDI a good stock to buy?

This page provides a data-driven analysis of QMS Medical Allied Services Limited (QMSMEDI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space